Iterum Therapeutics (ITRMF)
OTHER OTC:ITRMF
Want to see ITRMF full AI Analyst Report?
ITRMF Stock Chart & Stats
$0.34
-$0.04(-2.14%)
At close: 4:00 PM EST
$0.34
-$0.04(-2.14%)
Day’s Range― - ―
52-Week Range<$0.01 - $1.28
Previous CloseN/A
VolumeN/A
Average Volume (3M)813.22K
Market Cap
$2.11M
Enterprise Value$26.94M
Total Cash (Recent Filing)$11.00M
Total Debt (Recent Filing)$33.73M
Price to Earnings (P/E)―
Beta3.05
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.75
Shares Outstanding52,835,200
10 Day Avg. Volume1,119,323
30 Day Avg. Volume813,222
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-8.54
Price to Sales (P/S)0.00
P/FCF Ratio-1.30
Enterprise Value/Market Cap12.75
Enterprise Value/Revenue69.08
Enterprise Value/Gross Profit-40.33
Enterprise Value/Ebitda-1.17
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-0.31
Revenue Forecast (FY)$9.38M
Bulls Say, Bears Say
Bulls Say
Patent Expansion (China & Mexico)Extended patents in China and Mexico through 2039–2041 materially lengthen market exclusivity in key international jurisdictions. This strengthens long-term commercial upside, supports pricing power versus generics, and enhances licensing or partnering optionality across global markets.
Initial Prescriber Adoption Of OrlyndaMore than 280 prescriptions across 100 unique prescribers at launch indicates early clinical acceptance and real prescriber engagement. Durable prescriber adoption is critical for sustained uptake, repeat prescribing, and revenue scale as payer coverage and distribution expand.
Managed-care Rebate AgreementA rebate deal with a top Medicare Part D PBM materially improves payer access and formulary placement prospects beginning 2026/2027. Structural gains in coverage can raise fill rates, reduce out-of-pocket barriers, and support steadier prescription growth over multiple years.
Bears Say
Negative Shareholders' Equity And Elevated LeverageNegative equity and debt that exceeds assets constrain financial flexibility and increase refinancing and dilution risk. This capital-structure weakness can limit investment in commercial scale-up or R&D and raises vulnerability to adverse funding conditions over the next several quarters.
Ongoing Cash Burn And Capital NeedsSustained operating cash burn (~-$19.9M TTM) and management's plan to seek additional funding create execution risk. Reliance on new capital can dilute shareholders and, if market access tightens, could slow commercialization and delay achieving self-sustaining cash generation.
Nasdaq Listing Compliance / Delisting RiskActive non-compliance notices on market value and minimum bid price create a persistent governance and liquidity risk. A delisting or prolonged compliance process would impair access to U.S. capital markets, raise financing costs, and hamper long-term commercialization and investor confidence.
ITRMF FAQ
What was Iterum Therapeutics’s price range in the past 12 months?
Iterum Therapeutics lowest stock price was <$0.01 and its highest was $1.28 in the past 12 months.
What is Iterum Therapeutics’s market cap?
Iterum Therapeutics’s market cap is $2.11M.
When is Iterum Therapeutics’s upcoming earnings report date?
Iterum Therapeutics’s upcoming earnings report date is Aug 07, 2026 which is in 55 days.
How were Iterum Therapeutics’s earnings last quarter?
Currently, no data Available
Is Iterum Therapeutics overvalued?
According to Wall Street analysts Iterum Therapeutics’s price is currently Overvalued.
Does Iterum Therapeutics pay dividends?
Iterum Therapeutics does not currently pay dividends.
What is Iterum Therapeutics’s EPS estimate?
Iterum Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Iterum Therapeutics have?
Iterum Therapeutics has 52,835,200 shares outstanding.
What happened to Iterum Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Iterum Therapeutics?
Currently, no hedge funds are holding shares in ITRMF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Iterum Therapeutics
Iterum Therapeutics plc, an Irish pharmaceutical company founded in Dublin in 2015, is dedicated to the development and commercialization of treatments for bacterial infections that are resistant to existing drugs. Operating in Ireland, Bermuda, and the United States, the firm currently markets ORLYNVAH, an oral penem antibiotic. This medication is prescribed for adult women experiencing uncomplicated urinary tract infections (uUTIs) caused by specific microorganisms such as Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis, particularly when alternative oral antibacterial treatments are limited or unavailable. Furthermore, Iterum is actively progressing sulopenem, an innovative anti-infective compound. This drug, being developed in both oral and intravenous formulations, is intended to address a range of conditions, including uncomplicated and complicated urinary tract infections, complicated intra-abdominal infections, community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis, and pelvic inflammatory diseases. The company is currently in a state of reorganization.
ITRMF Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Cel-Sci
―
Clene
―
Xilio Therapeutics
―
CAMP4 Therapeutics Corporation
―
Radiopharm Theranostics Limited Sponsored ADR
―
Ownership Overview
0.46% Insiders
0.02% Mutual Funds
0.33% Other Institutional Investors
99.19% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---